3. Slater, A. F., Kimland, M., Jiang, S. A., and Orrenius, S. Constitutive nuclear NF 21.
B/rel DNA-binding activity of rat thymocytes is increased by stimuli that promote
apoptosis, but not inhibited by pyrrolidine dithiocarbamate. Biochem. J., 312: 833–
838, 1995. 22.
4. Wang, C. Y., Mayo, M. W., and Baldwin, A. S., Jr. TNF- and cancer therapy-induced
apoptosis: potentiation by inhibition of NF- B. Science (Wash. DC), 274: 784 –787,
1996.
23.
5. Wang, C. Y., Cusack, J. C., Jr., Liu, R., and Baldwin, A. S., Jr. Control of inducible
chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhi-24.
bition of NF- B. Nat. Med., 5: 412–417, 1999.
6. MacKeigan, J. P., Collins, T. S., and Ting, J. P-Y. MEK inhibition enhances
paclitaxel-induced tumor apoptosis. J. Biol. Chem., 275: 38953–38956, 2000.
25.
7. Torres, K., and Horwitz, S. B. Mechanisms of Taxol-induced cell death are concentration dependent. Cancer Res., 58: 3620 –3626, 1998.
8. Xia, Z., Dickens, M., Raingeaud, J., Davis, R. J., and Greenberg, M. E. Opposing 26.
effects of ERK and JNK-p38 MAP kinases on apoptosis. Science (Wash. DC), 270:
1326 –1331, 1995. 27.
9. Gupta, K., Kshirsagar, S., Li, W., Gui, L., Ramakrishnan, S., Gupta, P., Law, P. Y.,
and Hebbel, R. P. VEGF prevents apoptosis of human microvascular endothelial cells
via opposing effects on MAPK/ERK and SAPK/JNK signaling. Exp. Cell Res., 247: 28.
495–504, 1999.
10. Yu, C., Wang, S., Dent, P., and Grant, S. Sequence-dependent potentiation of
paclitaxel-mediated apoptosis in human leukemia cells by inhibitors of the mitogen- 29.
activated protein kinase kinase/mitogen-activated protein kinase pathway. Mol. Pharmacol., 60: 143–154, 2001.
11. Herrera, R., and Sebolt-Leopold, J. S. Unraveling the complexities of the Raf/MAP
30.
kinase pathway for pharmacological intervention. Trends Mol. Med., 8: S27–S31,
2002.
12. Sebolt-Leopold, J. S. Development of anticancer drugs targeting the MAP kinase
pathway. Oncogene, 19: 6594–6599, 2000.
31.
13. Sebolt-Leopold, J. S., Dudley, D. T., Herrera, R., Van Becelaere, K., Wiland, A.,
Gowan, R. C., Tecle, H., Barrett, S. D., Bridges, A., Przybranowski, S., et al.
Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat.
Med., 5: 810–816, 1999. 32.
14. Sivaraman, V. S., Wang, H., Nuovo, G. J., and Malbon, C. C. Hyperexpression of
mitogen-activated protein kinase in human breast cancer. J. Clin. Investig., 99:
1478 –1483, 1997. 33.
15. Mandell, J. W., Hussaini, I. M., Zecevic, M., Weber, M. J., and Van den Berg, S. R.
In situ visualization of intratumor growth factor signaling: immunohistochemical
localization of activated ERK/MAP kinase in glial neoplasms. Am. J. Pathol., 153: 34.
1411–1423, 1998.
16. Mansour, S. J., Matten, W. T., Hermann, A. S., Candia, J. M., Rong, S., Fukasawa,
K., Vande Woude, G. F., and Ahn, N. G. Transformation of mammalian cells by
constitutively active MAP kinase kinase. Science (Wash. DC), 265: 966 –970, 1994.
35.
17. Lewis, T. S., Hunt, J. B., Aveline, L. D., Jonscher, K. R., Louie, D. F., Yeh, J. M.,
Nahreini, T. S., Resing, K. A., and Ahn, N. G. Identification of novel MAP kinase
pathway signaling targets by functional proteomics and mass spectrometry. Mol. Cell,
36.
6: 1343–1354, 2000.
18. Hod, Y., Pentyala, S. N., Whyard, T. C., and El-Maghrabi, M. R. Identification and
characterization of a novel protein that regulates RNA-protein interaction. J. Cell.
37.
Biochem., 72: 435–444, 1999.
19. McDaid, H. M., and Horwitz, S. B. Selective potentiation of paclitaxel (Taxol)induced cell death by mitogen-activated protein kinase kinase inhibition in human
cancer cell lines. Mol. Pharmacol., 60: 290 –301, 2001.
20. Wang, H., Cao, R., Xia, L., Erdjument-Bromage, H., Borchers, C., Tempst, P., and 38.
Zhang, Y. Purification and functional characterization of a histone H3-lysine 4- specific methyltransferase. Mol. Cell, 8: 1207–1217, 2001.
